Related coverage linked through entity extraction aliases.
May 01, 2026
FDA grants Priority Review for Gilead's bictegravir/lenacapavir single-tablet HIV regimen. The NDA is supported by ARTISTRY-1 and ARTISTRY-2 trials showing noninferiority. A PDUFA target date of August 27, 2026 has been set.
Mar 25, 2026
Two research teams have developed catalytic methods for synthesizing chiral sulfur compounds with antiviral potential. One approach uses an organocatalytic strategy to create vinyl sulfinamides that bind to SARS-CoV-2 and HIV-1 proteins, while another employs copper catalysis for high-yield production of chiral sulfilimines. Both methods address critical gaps in accessing valuable chemical space for drug discovery.
Feb 27, 2026
Merck announced Phase 3 trial results for its investigational once-daily, two-drug HIV regimen doravirine/islatravir at CROI 2026, demonstrating non-inferiority to standard treatment in treatment-naïve adults with viral suppression rates of 91.8% at Week 48.
Feb 26, 2026
A once-daily single-tablet combination of bictegravir and lenacapavir demonstrated non-inferiority to existing HIV treatments in Phase 3 trials, offering simplified treatment for people living with HIV who are virologically suppressed.
Feb 13, 2026
An international research team has identified antibody 007, which targets HIV-1's V3 glycan site without depending on sugar structures the virus frequently alters, remaining effective against resistant variants and enhancing combination therapies.
